Introduction
Ventilator-associated pneumonia (VAP) is a significant concern in intensive care units, especially prevalent among brain-injured patients who are mechanically ventilated. With VAP incidence rates ranging from 22% to 71% depending on the study, and brain injury being a notable independent risk factor, the prevention of this infection is paramount.
Current standard of care includes a set of measures aiming to reduce the incidence of VAP; however, the challenge of early versus late onset VAP and the associated risk of multi-drug resistant organisms necessitate ongoing research and innovation in prophylactic strategies. The PROPHY-VAP trial is a pivotal study that explores the use of prophylactic antibiotics, specifically ceftriaxone, to prevent early-onset VAP in brain-injured patients.
One Sentence Summary
The PROPHY-VAP trial showed that a single dose of ceftriaxone can significantly reduce early-onset VAP in mechanically ventilated brain-injured patients, offering a potential change in clinical practice for VAP prevention.
The PROPHY-VAP Trial
| Parameter | Details |
|---|---|
|
Study Design
|
Multicentre, randomised, double-blind, placebo-controlled trial conducted across 9 French ICUs (October 2015 – May 2020) |
|
Population
|
Comatose adult patients (GCS ≤12) requiring mechanical ventilation post-acute brain injury. Excluded: high death risk within 48 hours, previous hospitalisations for coma, beta-lactam contraindications, and patients receiving antibiotics for pre-existing infections. |
|
Intervention
|
Treatment: Ceftriaxone 2 g IV (single dose) Control: Placebo Administered within 12 hours of tracheal intubation |
|
Primary Outcome
|
Incidence of early-onset VAP (day 2 to day 7 of mechanical ventilation) |
|
Sample Size
|
345 patients randomised 1:1 — 171 ceftriaxone, 174 placebo (319 included in final analysis) |
Key Results
Ceftriaxone Group
14%
Early VAP incidence
23 of 171 patients
Placebo Group
32%
Early VAP incidence
51 of 174 patients
Hazard Ratio
0.60
Significant reduction in early-onset VAP
Total 93 adjudicated VAP cases, of which 74 were early infections
No increase in multi-drug resistant organisms or adverse effects attributable to ceftriaxone
319 patients analysed: 166 men and 153 women
Clinical Pearl
The intervention was not only efficacious in reducing the incidence of early VAP but also safe for patients, with no additional risk of fostering antibiotic resistance. A single dose of ceftriaxone administered within 12 hours of intubation represents a simple, low-burden intervention.
Clinical Conclusions
Bottom Line
A single dose of ceftriaxone significantly reduces the risk of early VAP in brain-injured patients requiring mechanical ventilation, without adverse microbiological consequences. This supports the inclusion of early ceftriaxone in VAP prevention protocols for this population.
Early VAP incidence was reduced from 32% to 14% with a single dose of ceftriaxone 2 g IV administered within 12 hours of intubation (HR 0.60).
No increase in multi-drug resistant organisms was observed, addressing a key concern with prophylactic antibiotic strategies.
The findings have sparked debate regarding the broader implications of prophylactic antibiotic use, including the risk of over-diagnosis of VAP and the absence of data on late-onset VAP and resistant pathogens.
Further research is warranted before integrating these results into standard practice. The results provide a strong argument for including a single dose of ceftriaxone in VAP prevention bundles for brain-injured patients.
Full Reference List
- Francois B, et al. PROPHY-VAP: Prophylactic Antibiotic Use in Brain-Injured Patients to Prevent Ventilator-Associated Pneumonia — A Multicentre, Randomised, Double-Blind, Placebo-Controlled Trial. Lancet Respir Med. 2023. Full text
- Francois B, et al. PROPHY-VAP study protocol. BMC Pulm Med. 2018. Protocol
- Ehrmann S, et al. AMIKINHAL trial. N Engl J Med. 2023. Full text
Never Miss a Pearl
Get Pharmacy Pearls delivered weekly
Join 3,000+ pharmacists who receive curated clinical insights every Friday.